Cargando…
Development of combinatorial antibody therapies for diffuse large B cell lymphoma
Diffuse large B-cell lymphoma (DLBCL), the most common form of lymphoma, is typically treated with chemotherapy combined with the immunotherapy rituximab, an antibody targeting the B cell receptor, CD20. Despite the success of this treatment regimen, approximately a third of DLBCL patients experienc...
Autores principales: | Geanes, Eric S., Krepel, Stacey A., McLennan, Rebecca, Pierce, Stephen, Khanal, Santosh, Bradley, Todd |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637670/ https://www.ncbi.nlm.nih.gov/pubmed/36353222 http://dx.doi.org/10.3389/fmed.2022.1034594 |
Ejemplares similares
-
Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination
por: Geanes, Eric S., et al.
Publicado: (2022) -
Autoantibodies against Angiotensin-converting enzyme 2 and immune molecules are associated with COVID-19 disease severity
por: Bradley, Todd, et al.
Publicado: (2023) -
The cellular and immunological dynamics of early and transitional human milk
por: LeMaster, Cas, et al.
Publicado: (2023) -
Effects of Prior Infection with SARS-CoV-2 on B Cell Receptor Repertoire Response during Vaccination
por: Fraley, Elizabeth R., et al.
Publicado: (2022) -
Targeting Natural Killer Cells for Improved Immunity and Control of the Adaptive Immune Response
por: Pierce, Stephen, et al.
Publicado: (2020)